Radiopharmaceuticals Face Safety Concerns in Trials
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Radiopharmaceuticals were pitched as a way to deliver radiation directly to malignant tumors rather than blasting it across patients' entire bodies and damaging healthy tissue.
- The drug industry has seized on radiopharmaceuticals as a shining new field of drug development, attracting heavy attention as more therapies move into clinical trials.
- Isotopes powering radiopharmaceuticals are described as "just as virulent" as the beam radiation patients have begrudgingly tolerated for decades, despite being engineered for targeted delivery.
- Developers report radiopharmaceuticals are inadvertently damaging patients' kidneys, liver, or bone marrow while hurtling toward tumor targets.
- The safety concerns are surfacing as more radiopharmaceutical therapies enter clinical trials, complicating the field's foundational promise of precision targeting.
Why it matters: Documented kidney, liver, and bone marrow damage in clinical trials undercuts the precision-tumor pitch that has driven the drug industry's enthusiasm for radiopharmaceuticals — exposing a fundamental gap between the field's marketing and its emerging safety data.
Ask SkimNews
